„NovaHep envisions that engineering veins and arteries represents only the beginning of a new exciting era for individualized human tissues that eliminate the need for immunosuppression“
NovaHep’s technology would be especially advantageous in low-flow vascular beds, in veins with and without valves, and in case of vessels with <6 mm diameter (where artificial vessels work very poorly). NovaHep’s technology can also be used to make tissue-engineered arteries that may be expected to act physiologically as the arteries they are set to replace. Besides this “basic product range”, a range of related products can be envisioned.